All‐cause mortality (RR) · patients with chronic heart failure with preserved ejection fraction
Angiotensin receptor blockers (ARBs) showed no clear difference in all‐cause mortality (RR) compared with placebo or no treatment (high certainty).
1 finding from 1 review
All‐cause mortality (RR) · patients with chronic heart failure with preserved ejection fraction
Angiotensin‐converting enzyme inhibitors (ACEIs) showed no clear difference in all‐cause mortality (RR) compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Cardiovascular mortality · patients with chronic heart failure with preserved ejection fraction
Angiotensin receptor blockers (ARBs) showed no clear difference in cardiovascular mortality (RR) compared with placebo or no treatment (high certainty).
1 finding from 1 review
Cardiovascular mortality · patients with chronic heart failure with preserved ejection fraction
Angiotensin‐converting enzyme inhibitors (ACEIs) showed no clear difference in cardiovascular mortality (RR) compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
All‐cause mortality (RR) Range of · patients with chronic heart failure with preserved ejection fraction
Angiotensin receptor neprilysin inhibitors (ARNIs) leads to lower all‐cause mortality (RR) Range of compared with usual care (high certainty).
1 finding from 1 review
Cardiovascular mortality · patients with chronic heart failure with preserved ejection fraction
Angiotensin receptor neprilysin inhibitors (ARNIs) showed no clear difference in cardiovascular mortality (RR) Median compared with usual care (moderate certainty).
1 finding from 1 review
All‐cause short‐term mortality: at intensive care unit · adults with cardiogenic shock
It is very uncertain whether dopamine‐milrinone changes all‐cause short‐term mortality: at intensive care unit compared with dopamine‐dobutamine (very low certainty).
1 finding from 1 review
All‐cause mortality · patients with chronic heart failure with preserved ejection fraction
Mineralocorticoid receptor antagonists (MRAs) showed no clear difference in all‐cause mortality compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
All‐cause mortality · people with heart failure with reduced ejection fraction
Nurse‐led titration probably leads to lower all‐cause mortality compared with usual care (moderate certainty).
1 finding from 1 review
All‐cause mortality (RR) · patients with chronic heart failure with preserved ejection fraction
Beta‐blockers showed no clear difference in all‐cause mortality (RR) compared with placebo or no treatment (low certainty).
1 finding from 1 review
Cardiovascular mortality · patients with chronic heart failure with preserved ejection fraction
Beta‐blockers may leads to lower cardiovascular mortality (RR) compared with placebo or no treatment (low certainty).
1 finding from 1 review
Cardiovascular mortality · patients with chronic heart failure with preserved ejection fraction
Mineralocorticoid receptor antagonists (MRAs) showed no clear difference in cardiovascular mortality (RR) compared with placebo or no treatment (moderate certainty).
1 finding from 1 review